.svg)
How Ferrous Bisglycinate is Absorbed
The chelate transport pathway
Standard iron salts (such as ferrous sulfate and ferrous gluconate) are absorbed via divalent metal transporter 1 (DMT1) in the duodenum. This pathway is pH-sensitive and is inhibited by phytates, polyphenols, calcium, and other minerals competing for the same transporter. Ferrous bisglycinate is absorbed intact as a chelate — entering intestinal cells via peptide and amino acid transporters that are separate from DMT1. This alternative uptake route means the iron bypasses many of the inhibitors that reduce standard iron absorption.
Stability in the digestive tract
The glycine chelate is stable at neutral and alkaline pH, which means ferrous bisglycinate maintains its structure even in environments where iron salts would be oxidized or precipitate. This stability is thought to explain why ferrous bisglycinate can be taken with food without the significant absorption penalty seen with ferrous sulfate, and why it produces less irritation to the gastric mucosa.
Comparative bioavailability
Studies comparing ferrous bisglycinate to ferrous sulfate in iron-deficient populations generally show equivalent or superior ferritin response with bisglycinate at lower elemental iron doses. A systematic review and meta-analysis found that ferrous bisglycinate produced comparable improvements in hemoglobin and ferritin to ferrous sulfate at lower elemental iron doses, with significantly fewer gastrointestinal adverse events. In populations where absorption is compromised — such as those with low stomach acid or those taking proton pump inhibitors — the chelate transport route may offer a meaningful practical advantage.
Ferrous Bisglycinate Versus Other Iron Supplement Forms
- Ferrous sulfate — ~65 mg elemental iron per 325 mg tablet; absorbed via DMT1 (pH-dependent) with moderate to poor GI tolerability. Most prescribed and effective, but carries a high side-effect rate
- Ferrous bisglycinate — ~25–36 mg elemental iron; absorbed via chelate/amino acid transporters with good GI tolerability. Comparable ferritin response at lower dose with less constipation
- Ferrous gluconate — ~36 mg elemental iron per 325 mg tablet; absorbed via DMT1 (pH-dependent) with moderate GI tolerability. Better tolerated than sulfate but still pH-sensitive
- Ferric ammonium citrate — Variable elemental iron; requires reduction to Fe2+ before absorption with moderate GI tolerability. Generally less bioavailable than ferrous forms
- Ferric pyrophosphate (Accrufer) — 30 mg elemental iron; absorbed via a unique lipid-mediated pathway with good GI tolerability. Prescription product developed for IBD/CKD populations
- Heme iron polypeptide — Variable elemental iron; absorbed via the heme transport receptor with good GI tolerability. Derived from hemoglobin, highly bioavailable, and less commonly available
Who May Benefit from Ferrous Bisglycinate
People who cannot tolerate ferrous sulfate
Gastrointestinal side effects — nausea, constipation, dark stools, and abdominal cramping — are the primary reason people discontinue iron supplementation. Studies suggest that 30–50% of individuals prescribed ferrous sulfate report significant side effects that compromise adherence. Ferrous bisglycinate's improved tolerability profile makes it a practical alternative for individuals who have discontinued other forms due to side effects.
People with absorption concerns
Individuals with reduced gastric acid production (including those on proton pump inhibitors or H2 blockers), those with inflammatory bowel disease, and those with celiac disease or other malabsorptive conditions may absorb standard iron salts poorly. The chelate transport route used by ferrous bisglycinate offers an alternative pathway that is less dependent on luminal conditions.
Pregnant women and those with high iron demand
Iron requirements increase substantially during pregnancy. Ferrous bisglycinate is used in prenatal supplements and has been studied in pregnant populations, where its tolerability advantage is particularly relevant given that pregnancy already increases gastrointestinal sensitivity.
What to Test before and during Iron Supplementation
The appropriate iron dose and duration of supplementation depends on baseline iron status, which should be established through blood testing before beginning. Testing during supplementation allows assessment of response and prevents inadvertent over-repletion.
- Ferritin — Iron stores; primary endpoint of supplementation
- Serum iron — Circulating iron; fluctuates with recent intake and supplementation
- Transferrin saturation — Iron availability; elevated levels may indicate over-repletion
- TIBC — Total iron binding capacity; normalizes as stores are replenished
- Hemoglobin + MCV — Anemia resolution; objective marker of hematological response
Superpower's Baseline Blood Panel includes ferritin, serum iron, transferrin saturation, TIBC, hemoglobin, and MCV — the complete iron status picture. Reference ranges vary by laboratory and individual; all results should be interpreted by a qualified provider.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before beginning iron supplementation. Superpower offers blood panels that include the biomarkers discussed in this article. Links to individual tests are provided for informational context.
FAQs
Ferrous bisglycinate and ferrous sulfate produce comparable improvements in ferritin and hemoglobin when used in iron-deficient individuals, but ferrous bisglycinate generally achieves this at a lower elemental iron dose with significantly fewer gastrointestinal side effects. For individuals who tolerate ferrous sulfate well, either form is appropriate. For those who have difficulty with side effects or absorption, bisglycinate is often the preferred alternative.
Yes. One of the practical advantages of ferrous bisglycinate is that it can be taken with food without a significant reduction in absorption, unlike ferrous sulfate which is traditionally recommended on an empty stomach to maximize absorption. This makes it easier to maintain supplementation consistently without planning around meals.
Ferrous bisglycinate supplements typically provide 25 to 36 mg of elemental iron per serving, depending on the formulation. This is lower than the elemental iron in a standard ferrous sulfate tablet (65 mg per 325 mg tablet), but studies suggest the chelated form may produce comparable ferritin response at these lower doses due to its superior absorption efficiency.
Ferritin levels typically begin rising within 4 to 6 weeks of consistent supplementation. Full replenishment of depleted iron stores generally takes 3 to 6 months, depending on the severity of deficiency and individual absorption. Follow-up ferritin testing 2 to 3 months after beginning supplementation provides objective confirmation of response.
Constipation is possible with any iron supplement, but ferrous bisglycinate produces significantly less constipation than ferrous sulfate in head-to-head comparisons. The chelated structure means less free ionic iron contacts the intestinal lining, which reduces the disruption to gut motility that causes constipation with standard iron salts. If constipation does occur, increasing water intake and considering every-other-day dosing may help.
Ferrous bisglycinate has been studied in pregnant populations and is used in many prenatal supplement formulations. Its improved tolerability is particularly relevant during pregnancy, when gastrointestinal sensitivity is already heightened. As with any supplement during pregnancy, dosing should be guided by a healthcare provider based on confirmed iron status through blood testing.
References
- Fischer, J. A. J., Cherian, A. M., Bone, J. N., & Karakochuk, C. D. (2023). The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. Nutrition reviews, 81(8), 904-920. https://doi.org/10.1093/nutrit/nuac106
- Stoffel, N. U., Cercamondi, C. I., Brittenham, G., Zeder, C., Geurts-Moespot, A. J., Swinkels, D. W., Moretti, D., & Zimmermann, M. B. (2017). Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. The Lancet. Haematology, 4(11), e524-e533. https://doi.org/10.1016/S2352-3026(17)30182-5
- Milman, N., Jønsson, L., Dyre, P., Pedersen, P. L., & Larsen, L. G. (2014). Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. Journal of perinatal medicine, 42(2), 197-206. https://doi.org/10.1515/jpm-2013-0153
- Bumrungpert, A., Pavadhgul, P., Piromsawasdi, T., & Mozafari, M. R. (2022). Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. Nutrients, 14(3). https://doi.org/10.3390/nu14030452
- Puntarulo, S. (2005). Iron, oxidative stress and human health. Molecular aspects of medicine, 26(4-5), 299-312. https://doi.org/10.1016/j.mam.2005.07.001
.avif)
.svg)
.svg)
